Streetbeat News

Price Targets

KALV

HC Wainwright & Co. has reiterated its Buy rating for KalVista Pharma, maintaining a price target of $20. This suggests confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 10:58 am

DMAC

HC Wainwright & Co. has initiated coverage on DiaMedica Therapeutics with a Buy rating and set a price target of $7.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 10:52 am

EU

HC Wainwright & Co. has reiterated its Buy rating for enCore Energy, maintaining a price target of $7. This suggests confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 10:45 am

BNTX

HC Wainwright & Co. has maintained a Buy rating on BioNTech and raised its price target from $113 to $150, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 10:42 am

RYTM

HC Wainwright & Co. has reiterated its Buy rating for Rhythm Pharmaceuticals, maintaining a price target of $64. This suggests confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 10:32 am

ENTX

HC Wainwright & Co. has reiterated its Buy rating on Entera Bio (NASDAQ:ENTX) and maintained a price target of $10, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 10:31 am

TYRA

HC Wainwright & Co. has maintained a Buy rating on Tyra Biosciences and raised the price target from $25 to $30, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 10:23 am

ORKA

HC Wainwright & Co. has initiated coverage on Oruka Therapeutics with a Buy rating and set a price target of $45. This suggests a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 10:18 am

PAYO

Needham analyst Mayank Tandon maintains a Buy rating on Payoneer Global (NASDAQ:PAYO) and raises the price target from $9 to $10.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 10:07 am

ACCD

Needham analyst Ryan MacDonald has reiterated a Buy rating on Accolade (NASDAQ:ACCD) and maintained a price target of $8.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 10:04 am